{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T06:49:32Z","timestamp":1787986172277,"version":"build-2784847793"},"reference-count":91,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.clbc.2015.06.005","type":"journal-article","created":{"date-parts":[[2015,6,18]],"date-time":"2015-06-18T08:39:18Z","timestamp":1434616758000},"page":"413-420","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"title":["Genitourinary Syndrome of Menopause in Breast Cancer Survivors: Are We Facing New and Safe Hopes?"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1009-5309","authenticated-orcid":false,"given":"Nicoletta","family":"Biglia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina E.","family":"Bounous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca G.","family":"Sgro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"D'Alonzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Pecchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella E.","family":"Nappi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2015.06.005_bib1","first-page":"11","article-title":"Cancer Statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clbc.2015.06.005_bib2","unstructured":"American Cancer Society. Cancer Facts & Figures\u00a02014. Available at: http:\/\/www.cancer.org\/research\/cancerfactsstatistics\/cancerfactsfigures2014\/. Accessed October 24, 2014."},{"key":"10.1016\/j.clbc.2015.06.005_bib3","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1080\/13697130802244422","article-title":"A\u00a0survey among breast cancer survivors: treatment of the climacteric after breast cancer","volume":"11","author":"Antoine","year":"2008","journal-title":"Climacteric"},{"key":"10.1016\/j.clbc.2015.06.005_bib4","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1016\/j.ejca.2005.07.015","article-title":"Vaginal oestrogen therapy after breast cancer: is it safe?","volume":"41","author":"Ponzone","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2015.06.005_bib5","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2004.08.029","article-title":"Quality of life of postmenopausal women in the \u201cArimidex,\u201d Tamoxifen, Alone or in Combination (ATAC) adjuvant breast cancer trial","volume":"22","author":"Fallowfield","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2015.06.005_bib6","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/GME.0b013e31826560da","article-title":"Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer","volume":"20","author":"Baumgart","year":"2013","journal-title":"Menopause"},{"key":"10.1016\/j.clbc.2015.06.005_bib7","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10549-006-9260-6","article-title":"Quality of life of postmenopausal women in the ATAC (\u2018Arimidex\u2019, Tamoxifen Alone or in Combination) trial after completion of 5 years' adjuvant treatment for early stage breast cancer","volume":"100","author":"Cella","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2015.06.005_bib8","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1097\/GME.0b013e3182a122c2","article-title":"Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society","volume":"20","year":"2013","journal-title":"Menopause"},{"key":"10.1016\/j.clbc.2015.06.005_bib9","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1093\/annonc\/mdn353","article-title":"Practical guidelines for assessing and managing menopausal symptoms after breast cancer","volume":"19","author":"Hickey","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2015.06.005_bib10","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3109\/13697137.2010.522875","article-title":"Recommendations for the management of postmenopausal vaginal atrophy","volume":"13","author":"Sturdee","year":"2010","journal-title":"Climacteric"},{"key":"10.1016\/j.clbc.2015.06.005_bib11","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/gme.0b013e31824b970a","article-title":"The 2012 Hormone Therapy Position Statement of The North American Menopause Society Menopause","volume":"19","year":"2012","journal-title":"Menopause"},{"key":"10.1016\/j.clbc.2015.06.005_bib12","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3109\/13697137.2011.647840","article-title":"Vaginal Health: Insights, Views & Attitudes (VIVA) results from an international survey","volume":"15","author":"Nappi","year":"2012","journal-title":"Climacteric"},{"key":"10.1016\/j.clbc.2015.06.005_bib13","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/gme.0b013e3181a95581","article-title":"Efficacy and tolerability of local estrogen therapy for urogenital atrophy","volume":"17","author":"Archer","year":"2010","journal-title":"Menopause"},{"key":"10.1016\/j.clbc.2015.06.005_bib14","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/01.GME.0000117061.40493.AB","article-title":"Association of breast cancer and its therapy with menopause-related symptoms","volume":"11","author":"Crandall","year":"2004","journal-title":"Menopause"},{"key":"10.1016\/j.clbc.2015.06.005_bib15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0378-5122(03)00087-2","article-title":"Menopause after breast cancer: a survey on breast cancers survivors","volume":"45","author":"Biglia","year":"2003","journal-title":"Maturitas"},{"key":"10.1016\/j.clbc.2015.06.005_bib16","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/GME.0b013e318287342d","article-title":"Vaginal health in the United States: results from the Vaginal Health: Insights, Views & Attitudes survey","volume":"20","author":"Simon","year":"2013","journal-title":"Menopause"},{"key":"10.1016\/j.clbc.2015.06.005_bib17","first-page":"1790","article-title":"Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (Real Women's Views of Treatment Options for Menopausal Vaginal Changes) survey","volume":"10","author":"Kingsberg","year":"2013","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.clbc.2015.06.005_bib18","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1634\/theoncologist.11-2-96","article-title":"The influence of endocrine effects of adjuvant therapy on quality of life outcomes in younger breast cancer survivors","volume":"11","author":"Knobf","year":"2006","journal-title":"Oncologist"},{"key":"10.1016\/j.clbc.2015.06.005_bib19","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/01.GME.0000151655.10243.48","article-title":"Menopause symptoms and quality of life in women aged 45 to 65 years with and without breast cancer","volume":"12","author":"Conde","year":"2005","journal-title":"Menopause"},{"key":"10.1016\/j.clbc.2015.06.005_bib20","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3109\/13697137.2013.795683","article-title":"Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health","volume":"16","year":"2013","journal-title":"Climacteric"},{"key":"10.1016\/j.clbc.2015.06.005_bib21","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3109\/13697137.2014.946279","article-title":"Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and The North American Menopause Society","volume":"17","author":"Portman","year":"2014","journal-title":"Climacteric"},{"key":"10.1016\/j.clbc.2015.06.005_bib22","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.maturitas.2012.06.009","article-title":"EMAS clinical guide: low-dose vaginal estrogens for postmenopausal vaginal atrophy","volume":"73","author":"Rees","year":"2012","journal-title":"Maturitas"},{"key":"10.1016\/j.clbc.2015.06.005_bib23","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0140-6736(04)15493-7","article-title":"HABITS (hormonal replacement therapy after breast cancer\u2013is it safe?), a randomised comparison: trial stopped","volume":"363","author":"Holmberg","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2015.06.005_bib24","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/jnci\/dji071","article-title":"Menopausal hormone replacement therapy after breast cancer: the Stockholm randomised trial","volume":"97","author":"Von Schoultz","year":"2005","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2015.06.005_bib25","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/jnci\/djn058","article-title":"Increased risk of recurrence after hormone replacement therapy in breast cancer survivors","volume":"100","author":"Holmberg","year":"2008","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2015.06.005_bib26","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejca.2012.07.003","article-title":"Hormone replacement therapy after breast cancer: 10 year follow-up of the Stockholm randomised trial","volume":"49","author":"Fahl\u00e9n","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2015.06.005_bib27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.maturitas.2005.02.011","article-title":"Tibolone: clinical recommendations and practical guidelines. a report of the International Tibolone Consensus Group","volume":"51","author":"Kenemans","year":"2005","journal-title":"Maturitas"},{"key":"10.1016\/j.clbc.2015.06.005_bib28","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1470-2045(08)70341-3","article-title":"Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a doubleblind, randomised, non-inferiority trial","volume":"10","author":"Kenemans","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2015.06.005_bib29","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.maturitas.2011.09.003","article-title":"Effects of tibolone on climacteric symptoms and quality of life in breast cancer patients\u2013data from LIBERATE trial","volume":"70","author":"Sismondi","year":"2011","journal-title":"Maturitas"},{"key":"10.1016\/j.clbc.2015.06.005_bib30","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3109\/13697137.2012.657589","article-title":"The use of hormone therapy for the maintenance of urogynecological and sexual health post WHI","volume":"15","author":"Nappi","year":"2012","journal-title":"Climacteric"},{"key":"10.1016\/j.clbc.2015.06.005_bib31","first-page":"722","article-title":"Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee","volume":"92","author":"Cardozo","year":"1998","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.clbc.2015.06.005_bib32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3109\/09513590.2012.705389","article-title":"Vaginal atrophy in breast\u00a0cancer survivors: role of vaginal estrogen therapy","volume":"29","author":"Mariani","year":"2013","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.clbc.2015.06.005_bib33","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1524-4741.2011.01089.x","article-title":"Current overview of the management of urogenital atrophy in women with breast cancer","volume":"17","author":"Pruthi","year":"2011","journal-title":"Breast J"},{"key":"10.1016\/j.clbc.2015.06.005_bib34","first-page":"CD001500","article-title":"Local oestrogen therapy for vaginal atrophy in post menopausal women","author":"Suckling","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clbc.2015.06.005_bib35","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.maturitas.2008.11.015","article-title":"Reprint of Are all estrogens the same?","volume":"61","author":"Bennink","year":"2008","journal-title":"Maturitas"},{"key":"10.1016\/j.clbc.2015.06.005_bib36","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.maturitas.2014.01.004","article-title":"Effects of estriol on growth, gene expression and estrogen response element activation in human breast cancer cell lines","volume":"77","author":"Diller","year":"2014","journal-title":"Maturitas"},{"key":"10.1016\/j.clbc.2015.06.005_bib37","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/00042192-200205000-00006","article-title":"Treatment of urogenital atrophy with low-dose estradiol: preliminary results","volume":"9","author":"Santen","year":"2002","journal-title":"Menopause"},{"key":"10.1016\/j.clbc.2015.06.005_bib38","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/01.AOG.0000296714.12226.0f","article-title":"Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis. A randomised controlled trial","volume":"111","author":"Bachmann","year":"2008","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.clbc.2015.06.005_bib39","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3109\/13697137.2010.483297","article-title":"Minimized estradiol absorption with ultra-low dose 10 mcg 17 b-estradiol vaginal tablets","volume":"13","author":"Eugster-Mausmann","year":"2010","journal-title":"Climacteric"},{"key":"10.1016\/j.clbc.2015.06.005_bib40","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1097\/AOG.0b013e3181f386bb","article-title":"Endometrial safety of ultra-low dose estradiol vaginal tablets","volume":"116","author":"Simon","year":"2010","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.clbc.2015.06.005_bib41","first-page":"1","article-title":"Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels","volume":"17","author":"Santen","year":"2014","journal-title":"Climacteric"},{"issue":"suppl 1","key":"10.1016\/j.clbc.2015.06.005_bib42","first-page":"57","volume":"14","author":"Nieto","year":"2011","journal-title":"Climacteric"},{"key":"10.1016\/j.clbc.2015.06.005_bib43","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/gme.0b013e3182518e9a","article-title":"The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III study","volume":"19","author":"Cano","year":"2012","journal-title":"Menopause"},{"key":"10.1016\/j.clbc.2015.06.005_bib44","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.maturitas.2011.12.022","article-title":"Low dose estriol pessaries for the treatment of vaginal atrophy: a double-blind placebo-controlled trial investigating the efficacy of pessaries containing 0.2 mg and 0.03 mg estriol","volume":"71","author":"Griesser","year":"2012","journal-title":"Maturitas"},{"key":"10.1016\/j.clbc.2015.06.005_bib45","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S1470-2045(08)70256-0","article-title":"Symptom management in premenopausal patients with breast cancer","volume":"9","author":"Loprinzi","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2015.06.005_bib46","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-0-387-78818-0_2","article-title":"Adaptation to estradiol deprivation causes up-regulation of growth factor pathways and hypersensitivity to estradiol in breast cancer cells","volume":"630","author":"Santen","year":"2008","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.clbc.2015.06.005_bib47","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/annonc\/mdj127","article-title":"Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors","volume":"17","author":"Kendall","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2015.06.005_bib48","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/jnci\/93.10.754","article-title":"Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality","volume":"93","author":"O'Meara","year":"2001","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2015.06.005_bib49","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/cmt.6.1.45.52","article-title":"A\u00a0cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer","volume":"6","author":"Dew","year":"2003","journal-title":"Climateric"},{"key":"10.1016\/j.clbc.2015.06.005_bib50","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3109\/09513591003632258","article-title":"Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study","volume":"26","author":"Biglia","year":"2010","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.clbc.2015.06.005_bib51","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JOP.2011.000352","article-title":"Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator","volume":"8","author":"Wills","year":"2012","journal-title":"J\u00a0Oncol Pract"},{"key":"10.1016\/j.clbc.2015.06.005_bib52","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s10549-014-2930-x","article-title":"Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study","volume":"145","author":"Donders","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2015.06.005_bib53","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3109\/13697137.2010.529967","article-title":"Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients","volume":"14","author":"Pfeiler","year":"2011","journal-title":"Climacteric"},{"key":"10.1016\/j.clbc.2015.06.005_bib54","unstructured":"Clinicaltrials.gov [Web site]. Memorial Sloan-Kettering Cancer Center Clinical Trials. Serum estradiol levels in postmenopausal women with breast cancer receiving adjuvant aromatase inhibitors and vaginal estrogens. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00984399. Accessed January 08, 2015."},{"key":"10.1016\/j.clbc.2015.06.005_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/13697137.2014.991301","article-title":"Vaginal estriol\u2013lactobacilli combination and quality of life in endocrine-treated breast cancer","volume":"18","author":"Buchholz","year":"2015","journal-title":"Climacteric"},{"key":"10.1016\/j.clbc.2015.06.005_bib56","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.maturitas.2012.01.017","article-title":"Effect of one-month treatment with vaginal promestriene on serum estrone sulfate levels in cancer patients: a pilot study","volume":"72","author":"Del Pup","year":"2012","journal-title":"Maturitas"},{"key":"10.1016\/j.clbc.2015.06.005_bib57","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.3747\/co.2007.151","article-title":"Management of sexual dysfunction in postmenopaual breast cancer patients taking adjiuvant aromatase inhibitor therapy","volume":"14","author":"Derzko","year":"2007","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clbc.2015.06.005_bib58","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3109\/13697137.2012.756466","article-title":"Non-hormonal topical treatment of vulvovaginal atrophy: an up-to-date overview","volume":"16","author":"Sinha","year":"2013","journal-title":"Climacteric"},{"key":"10.1016\/j.clbc.2015.06.005_bib59","first-page":"549","article-title":"Simple strategies for vaginal health promotion in cancer survivors","volume":"8","author":"Carter","year":"2011","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.clbc.2015.06.005_bib60","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1200\/JCO.1997.15.3.969","article-title":"Phase III randomised double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer","volume":"15","author":"Loprinzi","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2015.06.005_bib61","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1097\/AOG.0b013e3182118790","article-title":"Vaginal pH-balanced gel for the control of atrophic vaginitis among breast cancer survivors: a randomized controlled trial","volume":"117","author":"Lee","year":"2011","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.clbc.2015.06.005_bib62","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1177\/1933719113497290","article-title":"Profile of ospemifene in the breast","volume":"20","author":"Berga","year":"2013","journal-title":"Reprod Sci"},{"key":"10.1016\/j.clbc.2015.06.005_bib63","unstructured":"European Medicines Agency. Available at: www.ema.europa.eu\/ema. Accessed April 24, 2015."},{"key":"10.1016\/j.clbc.2015.06.005_bib64","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/gme.0b013e3181c1ac01","article-title":"Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study","volume":"17","author":"Bachmann","year":"2010","journal-title":"Menopause"},{"key":"10.1016\/j.clbc.2015.06.005_bib65","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/gme.0b013e31826d36ba","article-title":"One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus","volume":"20","author":"Simon","year":"2012","journal-title":"Menopause"},{"key":"10.1016\/j.clbc.2015.06.005_bib66","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/gme.0b013e318279ba64","article-title":"Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy","volume":"20","author":"Portman","year":"2013","journal-title":"Menopause"},{"key":"10.1016\/j.clbc.2015.06.005_bib67","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3109\/13697137.2013.834493","article-title":"Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy","volume":"17","author":"Goldstein","year":"2014","journal-title":"Climacteric"},{"key":"10.1016\/j.clbc.2015.06.005_bib68","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0960-0760(01)00066-8","article-title":"In\u00a0vitro and in\u00a0vivo biologic effects of\u00a0ospemifene (FC-1271a) in breast cancer","volume":"77","author":"Taras","year":"2001","journal-title":"J\u00a0Steroid Biochem Mol Biol"},{"key":"10.1016\/j.clbc.2015.06.005_bib69","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1186\/bcr1317","article-title":"Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ","volume":"7","author":"Namba","year":"2005","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.clbc.2015.06.005_bib70","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jsbmb.2005.06.027","article-title":"Ospemifene inhibits the growth of dimethylbenzanthracene-induced mammary tumors in Sencar mice","volume":"97","author":"Wurz","year":"2005","journal-title":"J\u00a0Steroid Biochem Mol Biol"},{"key":"10.1016\/j.clbc.2015.06.005_bib71","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1210\/endo.141.2.7342","article-title":"Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats","volume":"141","author":"Qu","year":"2000","journal-title":"Endocrinology"},{"key":"10.1016\/j.clbc.2015.06.005_bib72","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/gme.0b013e318223e82a","article-title":"Ospemifene and 4-hydroxyospemifene effectively prevent and treat breast cancer in the MTag.Tg transgenic mouse model","volume":"19","author":"Burich","year":"2012","journal-title":"Menopause"},{"key":"10.1016\/j.clbc.2015.06.005_bib73","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.maturitas.2012.12.002","article-title":"Ospemifene, vulvovaginal atrophy, and breast cancer","volume":"74","author":"Wurz","year":"2013","journal-title":"Maturitas"},{"key":"10.1016\/j.clbc.2015.06.005_bib74","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jsbmb.2013.04.004","article-title":"Vaginal effects of ospemifene in the ovariectomized rat preclinical model of menopause","volume":"138","author":"Unkila","year":"2013","journal-title":"J\u00a0Steroid Biochem Mol Biol"},{"key":"10.1016\/j.clbc.2015.06.005_bib75","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s00404-011-2181-6","article-title":"Vaginal estrogen therapy in postmenopausal breast cancer patients treated with aromatase inhibitors","volume":"285","author":"Moegele","year":"2012","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.clbc.2015.06.005_bib76","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1634\/theoncologist.2010-0435","article-title":"Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I\/II study","volume":"16","author":"Witherby","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.clbc.2015.06.005_bib77","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1097\/gme.0b013e31819e8e2d","article-title":"Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy","volume":"16","author":"Labrie","year":"2009","journal-title":"Menopause"},{"key":"10.1016\/j.clbc.2015.06.005_bib78","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/jnci\/djk149","article-title":"Randomized clinical trial to evaluate transdermal testosterone in female cancer survivors with decreased libido. North Central Cancer Treatment Group Protocol N02C3","volume":"99","author":"Barton","year":"2007","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2015.06.005_bib79","doi-asserted-by":"crossref","first-page":"129","DOI":"10.5978\/islsm.14-OR-11","article-title":"Treatment of vaginal relaxation syndrome with an erbium:YAG laser using 90\u00b0 and 360\u00b0 scanning scopes: a pilot study and short-term results","volume":"23","author":"Lee","year":"2014","journal-title":"Laser Ther"},{"key":"10.1016\/j.clbc.2015.06.005_bib80","doi-asserted-by":"crossref","unstructured":"Salvatore S, Leone Roberti Maggiore U, Athanasiou S, et\u00a0al. Histological study on the effects of microablative fractional CO2 laser on atrophic vaginal tissue: an ex\u00a0vivo study. Menopause, Published online January 20,\u00a02015. [Epub ahead of print].","DOI":"10.1097\/GME.0000000000000401"},{"key":"10.1016\/j.clbc.2015.06.005_bib81","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3109\/13697137.2014.899347","article-title":"A\u00a012-week treatment with fractional CO 2 laser for vulvovaginal atrophy: a pilot study","volume":"17","author":"Salvatore","year":"2014","journal-title":"Climateric"},{"key":"10.1016\/j.clbc.2015.06.005_bib82","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3109\/13697137.2014.975197","article-title":"Sexual function after fractional microablative CO(2) laser in women with vulvovaginal atrophy","volume":"18","author":"Salvatore","year":"2015","journal-title":"Climacteric"},{"key":"10.1016\/j.clbc.2015.06.005_bib83","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3109\/13697137.2011.570590","article-title":"Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health","volume":"14","year":"2011","journal-title":"Climacteric"},{"key":"10.1016\/j.clbc.2015.06.005_bib84","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1016\/j.ejca.2012.10.004","article-title":"The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer","volume":"48","author":"Cardoso","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2015.06.005_bib85","first-page":"5","article-title":"Breast cancer and sexuality: multi-modal treatment options","volume":"9","author":"Krychman","year":"2012","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.clbc.2015.06.005_bib86","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10549-009-0398-x","article-title":"Addressing intimacy and partner communication after breast cancer: a randomized controlled group intervention","volume":"118","author":"Rowland","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2015.06.005_bib87","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/13697137.2013.871696","article-title":"Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause","volume":"17","author":"Nappi","year":"2014","journal-title":"Climacteric"},{"key":"10.1016\/j.clbc.2015.06.005_bib88","first-page":"3675","article-title":"Sexual complaints, pelvic floor symptoms, and sexual distress in women over forty","volume":"7","author":"Knoepp","year":"2010","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.clbc.2015.06.005_bib89","first-page":"470","article-title":"Can pelvic floor muscle training improve sexual function in women with pelvic organ prolapse? A randomized controlled trial","volume":"12","author":"Braekken","year":"2015","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.clbc.2015.06.005_bib90","first-page":"2549","article-title":"The acceptability, feasibility, and efficacy (phase I\/II study) of the OVERcome (Olive Oil, Vaginal Exercise, and MoisturizeR) intervention to improve dyspareunia and alleviate sexual problems in women with breast cancer","volume":"10","author":"Juraskova","year":"2013","journal-title":"J\u00a0Sex Med"},{"issue":"suppl 1","key":"10.1016\/j.clbc.2015.06.005_bib91","doi-asserted-by":"crossref","first-page":"1S","DOI":"10.1097\/AOG.0000000000000203","article-title":"A\u00a0solution for dyspareunia in breast cancer survivors: a randomized controlled study","volume":"123","author":"Goetsch","year":"2014","journal-title":"Obstet Gynecol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820915001214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820915001214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:14:00Z","timestamp":1761513240000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820915001214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":91,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S1526820915001214"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2015.06.005","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genitourinary Syndrome of Menopause in Breast Cancer Survivors: Are We Facing New and Safe Hopes?","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2015.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}